ClinicalTrials.gg
CompletedNCT02001181Updated Oct 15, 2015Results posted

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

A Phase 2 interventional study of Tofacitinib ointment 20mg/g and Placebo ointment (Vehicle) in Dermatitis, Atopic, sponsored by Pfizer. Completed at 5 sites in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2015-10-15.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
32nd of 47
69 · median 121
Started
2013
the only one that year
Phase 2
13 of 58
1 open now
Registered
5th of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 32nd largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2013, is one of 13 in phase 2, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Atopic Dermatitis
  • Atopic Eczema
  • Eczema
  • topical treatment
  • skin diseases
  • tofacitinib
  • CP-690
  • 550
  • Janus Kinase inhibitor
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at least 6 months prior to Day 1 that has been clinically stable for at least 1 month prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of Hanifin and Rajka.
  • Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.
  • Have atopic dermatitis on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs including palms and soles covering at least 2% of total body surface area (BSA) and up to and including 20% of total BSA at Day 1. At least 2% of the total BSA will need to be on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and soles).

Exclusion criteria

Exclusion Criteria:

  • Evidence of certain skin conditions/infections at baseline
  • Currently have atopic dermatitis on groin, genitals, palm or soles
  • Have certain laboratory abnormalities at baseline
  • Females who are pregnant, breastfeeding, or are of not using highly effective
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: Tofacitinib ointment 20mg/g

  • Placebo comparator
    Treatment B

    Drug: Placebo ointment (Vehicle)

Interventions

  • DrugTofacitinib ointment 20mg/g

    Drug page: Tofacitinib

    Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks

  • DrugPlacebo ointment (Vehicle)

    Placebo ointment (vehicle) twice daily (BID) for 4 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4

    The EASI quantifies the severity of a participant's atopic dermatitis based on both lesion severity and the percent of BSA affected. The EASI is a composite scoring by the atopic dermatitis clinical evaluator of the degree of erythema, induration/papulation, excoriation, and lichenification (each scored separately) for each of 4 body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of atopic dermatitis. What is reported is the percent change from baseline in EASI scores.

    Time frame: Baseline (pre-dose on Day 1) and Week 4

Secondary outcomes

  1. Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear at Week 4

    The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.

    Time frame: Week 4

  2. Proportion of Participants With Response of Clear or Almost Clear and Greater Than or Equal to (>=) 2 Grade/Point Improvement From Baseline at Week 4

    The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.

    Time frame: Baseline (pre-dose on Day 1) and Week 4

  3. Percent Change From Baseline in Body Surface Area (BSA) Efficacy at Week 4

    The percent BSA with atopic dermatitis in a body region was determined by the number of handprints of atopic dermatitis skin in that region: head and neck, upper limbs, trunk including axillae, lower limbs including buttocks. In the handprint method, the full palmar hand of the participant (i.e., the participant's fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. What is reported is the percent change from baseline in BSA affected.

    Time frame: Baseline (pre-dose on Day 1) and Week 4

  4. Change From Baseline in the EASI Clinical Signs Severity Sum Score at Week 4

    The EASI Clinical Signs Severity Sum Score was derived from the EASI. The Clinical Signs Severity Scores on the 4-point scale for dermatitis lesions were summed in each EASI body region. The sum of the Clinical Signs Severity Score in each EASI body region was then totaled across the 4 EASI body regions to provide an EASI Clinical Signs Severity Sum Score, which ranged from 0 to 48, with higher scores representing greater severity of atopic dermatitis.

    Time frame: Baseline (pre-dose on Day 1) and Week 4

07

Results

Posted Oct 15, 2015

Participant flow

Eligibility included male or female participants, 18 to 60 years of age (inclusive), who had a clinical diagnosis of atopic dermatitis for at least 6 months and clinically stable for \>=1 month.

Participant flow — Overall Study
MilestoneTofacitinib 20 mg/g BIDVehicle BID
Started3534
Completed3431
Not completed13
Withdrew: Adverse event02
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4

The EASI quantifies the severity of a participant's atopic dermatitis based on both lesion severity and the percent of BSA affected. The EASI is a composite scoring by the atopic dermatitis clinical evaluator of the degree of erythema, induration/papulation, excoriation, and lichenification (each scored separately) for each of 4 body regions, with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of atopic dermatitis. What is reported is the percent change from baseline in EASI scores.

Time frame:
Baseline (pre-dose on Day 1) and Week 4
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4
percent changeTofacitinib 20 mg/g BIDVehicle BID
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 4-81.7 ± 6.31-29.9 ± 6.46
Statistical analysis
  • Tofacitinib 20 mg/g BID vs Vehicle BID · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -51.8 · 80% CI -62.8 to -40.8The mixed model for repeated measures analysis included all the participants in FAS.
SecondaryProportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear at Week 4

The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear at Week 4
percentage of participantsTofacitinib 20 mg/g BIDVehicle BID
Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost Clear at Week 471.420.6
SecondaryProportion of Participants With Response of Clear or Almost Clear and Greater Than or Equal to (>=) 2 Grade/Point Improvement From Baseline at Week 4

The PGA score assesses the overall severity of atopic dermatitis. Scores range from 0 to 4 and correspond to a category (clear, almost clear, mild, moderate, and severe, respectively) based on morphological descriptors.

Time frame:
Baseline (pre-dose on Day 1) and Week 4
Reported as:
Number · percentage of participants
Proportion of Participants With Response of Clear or Almost Clear and Greater Than or Equal to (>=) 2 Grade/Point Improvement From Baseline at Week 4
percentage of participantsTofacitinib 20 mg/g BIDVehicle BID
Proportion of Participants With Response of Clear or Almost Clear and Greater Than or Equal to (>=) 2 Grade/Point Improvement From Baseline at Week 465.711.8
SecondaryPercent Change From Baseline in Body Surface Area (BSA) Efficacy at Week 4

The percent BSA with atopic dermatitis in a body region was determined by the number of handprints of atopic dermatitis skin in that region: head and neck, upper limbs, trunk including axillae, lower limbs including buttocks. In the handprint method, the full palmar hand of the participant (i.e., the participant's fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. What is reported is the percent change from baseline in BSA affected.

Time frame:
Baseline (pre-dose on Day 1) and Week 4
Reported as:
Mean · percent change
Percent Change From Baseline in Body Surface Area (BSA) Efficacy at Week 4
percent changeTofacitinib 20 mg/g BIDVehicle BID
Percent Change From Baseline in Body Surface Area (BSA) Efficacy at Week 4-72.7 ± 34.1-30.2 ± 39.4
SecondaryChange From Baseline in the EASI Clinical Signs Severity Sum Score at Week 4

The EASI Clinical Signs Severity Sum Score was derived from the EASI. The Clinical Signs Severity Scores on the 4-point scale for dermatitis lesions were summed in each EASI body region. The sum of the Clinical Signs Severity Score in each EASI body region was then totaled across the 4 EASI body regions to provide an EASI Clinical Signs Severity Sum Score, which ranged from 0 to 48, with higher scores representing greater severity of atopic dermatitis.

Time frame:
Baseline (pre-dose on Day 1) and Week 4
Reported as:
Mean · units on a scale
Change From Baseline in the EASI Clinical Signs Severity Sum Score at Week 4
units on a scaleTofacitinib 20 mg/g BIDVehicle BID
Change From Baseline in the EASI Clinical Signs Severity Sum Score at Week 4-11.4 ± 5.3-4.1 ± 4.5

Adverse events

Collected over Baseline up to 28 days after last study drug administration. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 20 mg/g BID—0/35 (0%)11/35 (31.4%)
Vehicle BID—0/34 (0%)19/34 (55.9%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTofacitinib 20 mg/g BIDVehicle BID
Blood creatine phosphokinase increasedInvestigations0/353/34
Dermatitis contactSkin and subcutaneous tissue disorders0/353/34
NasopharyngitisInfections and infestations2/352/34
HeadacheNervous system disorders1/352/34
Conjunctivitis allergicEye disorders0/351/34
Application site pruritusGeneral disorders1/351/34
Seasonal allergyImmune system disorders0/351/34
Upper respiratory tract infectionInfections and infestations0/351/34
Arthropod biteInjury, poisoning and procedural complications0/351/34
SunburnInjury, poisoning and procedural complications0/351/34

Baseline characteristics

The full analysis set included all participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Tofacitinib 20 mg/g BIDVehicle BIDTotal
Mean32.4 ± 9.830.4 ± 10.431.4 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 20 mg/g BIDVehicle BIDTotal
Female191837
Male161632
08

Study locations

5 sites
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 1Z2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain
    Quebec, G1V 4X7, Canada
09

References and documents

Publications

  • Purohit VS, Ports WC, Wang C, Riley S. Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning. J Clin Pharmacol. 2019 Jun;59(6):811-820. doi: 10.1002/jcph.1360. Epub 2018 Dec 17. PubMed 30556911 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2013
First posted
Dec 4, 2013
Start
Dec 2013
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Oct 15, 2015
Last update
Oct 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02001181
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 4, 2013
Start date
Dec 2013
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Oct 15, 2015
Last update
Oct 15, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion